Artigos de Perspetiva
Genética e Oncologia: Uma Viagem a Dois
Conteúdo principal do artigo
Marta Amorim
Detalhes do artigo
Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição 4.0.
Referências
Ordem dos Médicos [consultado Jan 2023] Disponível em: https://ordemdosmedicos.pt/resenha-historica-do-reconhecimento-da-especialidade-de-genetica-medica/ (2014).
Max Roser and Hannah Ritchie - "Cancer". OurWorldInData.org. [consultado Jan 2023] Disponível em: https://ourworldindata.org/cancer
Basu NN, Hodson J, Chatterjee S, Gandhi A, Wisely J, Harvey J, et al. The Angelina Jolie effect: Contralateral risk-reducing mastectomy trends in patients at increased risk of breast cancer. Sci Rep. 2021;11:2847. doi: 10.1038/s41598-021-82654-x.
Liede A, Cai M, Crouter TF, Niepel D, Callaghan F, Evans DG. Risk-reducing mastectomy rates in the US: a closer examination of the Angelina Jolie effect. Breast Cancer Res Treat. 2018;171:435-42. doi: 10.1007/s10549-018-4824-9.
Xi Q, Jin S, Morris S. Economic evaluations of predictive genetic testing: A scoping review. PLoS One. 2023;18:e0276572. doi: 10.1371/journal.pone.0276572.
Brown NA, Elenitoba-Johnson KS. Enabling Precision Oncology Through Precision Diagnostics. Annu Rev Pathol. 2020;15:97-121. doi: 10.1146/annurev-pathmechdis-012418-012735.
Ngeow J, Eng C. Precision medicine in heritable cancer: when somatic tumour testing and germline mutations meet. NPJ Genom Med. 2016;1:15006. doi: 10.1038/npjgenmed.2015.6. P
Rose M, Burgess JT, O'Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance. Front Cell Dev Biol. 2020;8:564601. doi: 10.3389/fcell.2020.564601.
Chakravarty D, Johnson A, Sklar J, Lindeman NI, Moore K, Ganesan S, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2022;40:1231-58. doi: 10.1200/JCO.21.02767. Erratum in: J Clin Oncol. 2022;40:2068.
Food and Drug Administration. Novel Drug Approvals for 2023. [consultado Jan 2023] Disponível em:https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023
Cohen SA, Liu MC, Aleshin A. Practical recommendations for using ctDNA in clinical decision making. Nature. 2023;619:259-68. doi: 10.1038/s41586-023-06225-y.
Brito-Rocha T, Constâncio V, Henrique R, Jerónimo C. Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests. Cells. 2023;12:935. doi: 10.3390/cells12060935.
Padrik P, Puustusmaa M, Tõnisson N, Kolk B, Saar R, Padrik A, et al. Implementation of Risk-Stratified Breast Cancer Prevention With a Polygenic Risk Score Test in Clinical Practice. Breast Cancer. 2023;17:11782234231205700. doi: 10.1177/11782234231205700. P
Dixon P, Keeney E, Taylor JC, Wordsworth S, Martin RM. Can polygenic risk scores contribute to cost-effective cancer screening? A systematic review. Genet Med. 2022;24:1604-17. doi: 10.1016/j.gim.2022.04.020.
